Company news
Nippon Shinyaku Co., Ltd. (TSE:4516) news
Every Nippon Shinyaku Co., Ltd. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Nippon Shinyaku : SAKIGAKE Pharmaceutical Product (Pioneering Drug) Designation Granted to NS-035 for the Treatment of Fukuyama Congenital Muscular Dystrophy
August 26, 2026
Notice Regarding Completion of Disposal of Treasury Stock as Restricted Stock Compensation
August 19, 2026
Nippon Shinyaku : Regarding the U.S. Litigation Concerning CAP-1002 (deramiocel) – U.S. Court Denies Motion for Preliminary Injunction and Refers Dispute to Arbitration
August 9, 2026
Consolidated Financial Results for the First Quarter of Fiscal Year 2026(IFRS)
August 5, 2026
Nippon Shinyaku : Exercises Option Rights for Commercialization of AB2 Bio’s Tadekinig alfa in the U.S.
July 30, 2026
Nippon Shinyaku : Enters into an Exclusive License Agreement for the Development, Manufacturing, and Commercialization of NS-025 Worldwide
July 22, 2026
Notice Regarding Disposal of Treasury Stock as Restricted Stock Compensation
July 21, 2026
Nippon Shinyaku : and Elixirgen Enter into an Option Agreement for Development and Commercialization of EXG-7001 for Duchenne Muscular Dystrophy
June 26, 2026
Nippon Shinyaku : Enters into a Sponsored Research Agreement with Boston Children’s Hospital
June 23, 2026
Nippon Shinyaku : Orphan Drug Designation granted to NS-035 for the Treatment of Fukuyama congenital muscular dystrophy in Japan
June 23, 2026
Nippon Shinyaku : Outline of Consolidated Financial Results for the Year Ended March 31, 2026
May 14, 2026
Nippon Shinyaku : Announcement of a Lawsuit Filed against Nippon Shinyaku
May 8, 2026
Nippon Shinyaku : Enters Collaboration with xFOREST Therapeutics on Drug Discovery Research Targeting RNA Structures
April 10, 2026
Nippon Shinyaku : start co-promotion activities of OPSUMIT® Pediatric Dispersible Tablets 1mg and 2.5mg for the Treatment of Pulmonary Arterial Hypertension
March 17, 2026
Nippon Shinyaku : Transfer of Marketing Authorization for Epileptic Seizures treatment FINTEPLA® Oral Solution 2.2 mg/mL
February 23, 2026
Nippon Shinyaku : Notice Regarding Executive Personnel Changes
February 9, 2026
Nippon Shinyaku : Outline of Consolidated Financial Results for the Third Quarter Ended December 31, 2025
February 8, 2026
Nippon Shinyaku : ELZONRIS® I.V. Injection Receives Marketing Approval for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm in Japan
December 22, 2025
Brogidirsen (NS-089/NCNP-02) 3.5 Year Clinical Trial Data for the Treatment of Duchenne Muscular Dystrophy Presented at 2025 World Muscle Society Congress
October 14, 2025
Nippon Shinyaku : Orphan Drug Designation granted to Buloxibutid for the Treatment of Idiopathic Pulmonary Fibrosis in Japan
September 30, 2025
Nippon Shinyaku : FDA Grants Orphan Drug Designation to NS-051/NCNP-04 for the Treatment of Duchenne Muscular Dystrophy
September 19, 2025
FDA Grants Fast Track Designation to NS-229 for the Treatment of Eosinophilic Granulomatosis with Polyangiitis
September 9, 2025
NS Pharma Announces Strategic Alliance with Boston Children's Hospital to Develop New Therapies for Rare Diseases
July 1, 2025